Last reviewed · How we verify
Ziprasidone Injection
Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.
Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Acute agitation associated with schizophrenia, Acute agitation associated with bipolar disorder.
At a glance
| Generic name | Ziprasidone Injection |
|---|---|
| Also known as | Zeldox, Geodon, Geodon, Zeldox |
| Sponsor | Hennepin Healthcare Research Institute |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Ziprasidone antagonizes dopamine D2 receptors, which reduces psychotic symptoms, and also blocks serotonin 5-HT2A receptors, which may improve mood and reduce extrapyramidal side effects. The intravenous formulation allows rapid onset of action for acute agitation or psychotic episodes in hospitalized patients.
Approved indications
- Acute agitation associated with schizophrenia
- Acute agitation associated with bipolar disorder
Common side effects
- Somnolence
- Headache
- Dizziness
- Nausea
- Extrapyramidal symptoms
- QT prolongation
- Orthostatic hypotension
Key clinical trials
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- Treatment of Schizophrenic Patients With Ziprasidone
- A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation (PHASE3)
- Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone (NA)
- Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PHASE4)
- Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation
- The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation (PHASE4)
- Switching Medication to Treat Schizophrenia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ziprasidone Injection CI brief — competitive landscape report
- Ziprasidone Injection updates RSS · CI watch RSS
- Hennepin Healthcare Research Institute portfolio CI